Skip to main content

Week in Review: BeiGene Raises $3.5 Billion in Shanghai STAR Board IPO

Deals and Financings   Beijing 's BeiGene priced its Shanghai STAR Exchange IPO to raise $3.5 billion to support its portfolio of more than 40 cancer candidates; Suzhou Abogen Biosciences closed a $300 million C+ round to develop its COVID-19 vaccine following a $720 million funding in August; Ablaze Pharma, a Shanghai-San Diego company, completed a $75 million Series A round for tumor targeting radiopharmaceutical therapies; SanReno Therapeutics, a China JV, was formed by Chinook and a syndicate that invested $40 million to bring two Chinook kidney drugs to China ; Nanjing Help Therapeutics raised $25 million in a C Round to advance its iPSC stem cell programs for heart failure and oncology immunotherapies; Shanghai iTabMed completed the spin-off of the its oncology immunotherapy platform from Evive Biotech and raised $20 million in a Series A financing; Hangzhou Sciwind Biosciences in-licensed global rights to Sanofi's portfolio of long-lasting GIP receptor agonists for NASH and other metabolic conditions;  Trials and Approvals   Ascentage Pharma and Innovent Biologics, two Suzhou biopharmas, announced  China  marketing approval of olverembatinib for leukemia; Suzhou Tot Biopharm announced that its Avastin biosimilar, Pusintin®, has been approved to launch in  China ; Hangzhou Lynk Pharma started a China Phase II trial of a targeted kinase inhibitor in patients with rheumatoid arthritis; MingMed, a  Guangzhou  biopharma, has been approved to start US clinical trials of its cancer immunotherapy, a small-molecule HPK1 inhibitor.  Stock Symbols: (NSDQ: BGNE; HK: 06160) (NSDQ: KDNY) (HK: 6855) (HK: 01801) (HK: 1875) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.